The estimated Net Worth of Rita Jain is at least $671 Thousand dollars as of 15 June 2024. Rita Jain owns over 4,534 units of ChemoCentryx Inc stock worth over $235,723 and over the last 7 years he sold CCXI stock worth over $0. In addition, he makes $434,846 as Independent Director at ChemoCentryx Inc.
Rita has made over 6 trades of the ChemoCentryx Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 4,534 units of CCXI stock worth $235,723 on 15 June 2024.
The largest trade he's ever made was exercising 7,726 units of ChemoCentryx Inc stock on 20 May 2022 worth over $401,675. On average, Rita trades about 1,307 units every 62 days since 2017. As of 15 June 2024 he still owns at least 4,534 units of ChemoCentryx Inc stock.
You can see the complete history of Rita Jain stock trades at the bottom of the page.
Dr. Rita I. Jain M.D. serves as Independent Director of the Company. serves as Independent Director of the Company. From May 2017 until June 2019, Dr. Jain served as Senior Vice President and Chief Medical Officer of Akebia Therapeutics, Inc., a biotechnology company. Prior to joining Akebia, Dr. Jain was Vice President of Men’s and Women’s Health and Metabolic Development at AbbVie, Inc. From 2003 to 2016 she held positions of increasing responsibility, with over 10 years as either a Divisional Vice President or Vice President in Pharmaceutical Development at Abbott Laboratories, and after AbbVie’s split from Abbott, at AbbVie. In addition to her work in Men’s and Women’s Health, and Metabolic Development, Dr. Jain also led activities in Pain, Respiratory, and Cystic Fibrosis Development. Before AbbVie, she held management positions in the Arthritis, Inflammation and Pain Group at Searle (acquired by Pharmacia and subsequently Pfizer). Prior to joining Searle, Dr. Jain was a faculty member at North Shore University Hospital in New York, with an academic appointment as Assistant Professor of Medicine, New York University School of Medicine. Dr. Jain received her B.S. in biology from LIU/C.W. Post and her M.D. from the State University of New York at Stony Brook School of Medicine. Dr. Jain completed her medical training in internal medicine at Staten Island University Hospital followed by a Fellowship in Rheumatology at North Shore University Hospital and a Clinical Research Fellowship at the University of Texas Southwestern Medical Center, Dallas. Jain is qualified to serve on our board of directors because of her experience in the healthcare industry and management experience from her service as the Chief Medical Officer of a public pharmaceutical company.
As the Independent Director of ChemoCentryx Inc, the total compensation of Rita Jain at ChemoCentryx Inc is $434,846. There are 6 executives at ChemoCentryx Inc getting paid more, with Thomas Schall having the highest compensation of $3,341,860.
Rita Jain is 57, he's been the Independent Director of ChemoCentryx Inc since 2019. There are 10 older and 2 younger executives at ChemoCentryx Inc. The oldest executive at ChemoCentryx Inc is Henry McKinnell, 77, who is the Independent Director.
Rita's mailing address filed with the SEC is C/O ANAPTYSBIO, INC., 10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA, 92121.
Over the last 13 years, insiders at ChemoCentryx Inc have traded over $355,980,520 worth of ChemoCentryx Inc stock and bought 3,166,975 units worth $19,475,662 . The most active insiders traders include Plc Gsk, Rishi Gupta, and (International) Ltd Vifor P.... On average, ChemoCentryx Inc executives and independent directors trade stock every 12 days with the average trade being worth of $4,175,785. The most recent stock trade was executed by Susan M Kanaya on 16 August 2022, trading 19,898 units of CCXI stock currently worth $216,092.
ChemoCentryx is a biopharmaceutical company developing new medications for inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies. ChemoCentryx's lead drug candidate, avacopan (CCX168), successfully completed a pivotal Phase III trial in ANCA-associated vasculitis and a New Drug Application is under review by the U.S. Food and Drug Administration. Avacopan is also in late stage clinical development for the treatment of severe Hidradenitis Suppurativa and C3 glomerulopathy (C3G). ChemoCentryx also has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer.
ChemoCentryx Inc executives and other stock owners filed with the SEC include: